Refresh Plus

Phase 3Small molecule

AbbVie

Refresh Plus is one of 48 small molecule programs targeting Cystoid Macular Edema. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystoid Macular EdemaActive, not recruiting

Eye DiseaseActive, not recruiting

Cystoid Macular EdemaPhase 2

Active, not recruiting

Eye DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

200 competitors in Eye Disease

#DrugCompanyPhaseTrials

Chantix

Pfizer

Phase 3

2 2

Alphagan

AbbVie

Phase 3

2 3

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 4

CF101

CCan-Fite BioPharma

Phase 3

1 5

Carboxymethylcellulose

AbbVie

Phase 3

4 6

Cenegermin

DDompé Farmaceutici S.p.A

Phase 3

1 7

Csa

ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

Phase 3

1 8

Diquafosol Tetrasodium

Merck & Co.

Phase 3

3 9

REFRESH LIQUIGEL

AbbVie

Phase 3

2 10

ABBV-444

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystoid Macular Edema1 trial

Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.

Withdrawn·JJohns Hopkins University·Phase 2·NCT00438243

Eye Disease1 trial

Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT04393441·400 enrolled

Acupuncture1 trial

Acupuncture for Dry Eye

Completed·KKorea Institute of Oriental Medicine·Phase 3·NCT01105221·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Refresh Plus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Refresh Plus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Refresh Plus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AbbVie

Refresh Plus

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystoid Macular Edema1 trial

Eye Disease1 trial

Acupuncture1 trial

References

Drug Info

Quick Facts

Related News